Document Type
Article
Publication Date
2-15-2023
Abstract
Visceral pain (VP) is a global problem with complex etiologies and limited therapeutic options. Guanylyl cyclase C (GUCY2C), an intestinal receptor producing cyclic GMP(cGMP), which regulates luminal fluid secretion, has emerged as a therapeutic target for VP. Indeed, FDA-approved GUCY2C agonists ameliorate VP in patients with chronic constipation syndromes, although analgesic mechanisms remain obscure. Here, we revealed that intestinal GUCY2C was selectively enriched in neuropod cells, a type of enteroendocrine cell that synapses with submucosal neurons in mice and humans. GUCY2Chi neuropod cells associated with cocultured dorsal root ganglia neurons and induced hyperexcitability, reducing the rheobase and increasing the resulting number of evoked action potentials. Conversely, the GUCY2C agonist linaclotide eliminated neuronal hyperexcitability produced by GUCY2C-sufficient - but not GUCY2C-deficient - neuropod cells, an effect independent of bulk epithelial cells or extracellular cGMP. Genetic elimination of intestinal GUCY2C amplified nociceptive signaling in VP that was comparable with chemically induced VP but refractory to linaclotide. Importantly, eliminating GUCY2C selectively in neuropod cells also increased nociceptive signaling and VP that was refractory to linaclotide. In the context of loss of GUCY2C hormones in patients with VP, these observations suggest a specific role for neuropod GUCY2C signaling in the pathophysiology and treatment of these pain syndromes.
Recommended Citation
Barton, Joshua R.; Londregran, Annie K.; Alexander, Tyler D.; Entezari, Ariana A.; Bar-Ad, Shely; Cheng, Lan; Lepore, Angelo C.; Snook, Adam E.; Covarrubias, Manuel; and Waldman, Scott A., "Intestinal Neuropod Cell GUCY2C Regulates Visceral Pain" (2023). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 151.
https://jdc.jefferson.edu/petfp/151
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
36548082
Language
English
Comments
This article is the author's final published version in The Journal of Clinical Investigation, Volume 133, Issue 4, February 2023, Article number e165578.
The published version is available at https://doi.org/10.1172/JCI165578. Copyright © 2023 Barton et al.